Physician profile
Ryan L Weir
NPI 1285127696
$781.50
in general payments reported to CMS, 2019-2025
16 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.13 · 2023: $218 · 2024: $406 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $191.92 | 2023-2024 | Trintellix |
| Viiv Healthcare Company | $133.27 | 2024 | Cabenuva |
| Astrazeneca Pharmaceuticals LP | $78.43 | 2022-2024 | Farxiga, Airsupra |
| Dexcom, INC. | $57.46 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $52.51 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $49.33 | 2022-2024 | Evenity, Prolia |
| Gilead Sciences, INC. | $46.51 | 2023-2024 | |
| Lilly USA, LLC | $33.19 | 2022-2025 | Mounjaro |
| Abbvie INC. | $32.47 | 2023 | Ubrelvy |
| Edwards Lifesciences Corporation | $18.75 | 2024 | Sapien 3 Ultra Resilia |
| Verona Pharma, INC. | $16.78 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.73 | 2024 | Jardiance, Synjardy |
| Mylan Specialty L.P. | $15.62 | 2023 | Yupelri |
| Currax Pharmaceuticals LLC | $14.50 | 2025 | Contrave |
| Pfizer INC. | $13.76 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $10.27 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.